NASDAQ:RSLS ReShape Lifesciences Q2 2025 Earnings Report $3.16 -0.05 (-1.41%) Closing price 08/14/2025Extended Trading$3.16 0.00 (0.00%) As of 08/14/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History ReShape Lifesciences EPS ResultsActual EPS-$9.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AReShape Lifesciences Revenue ResultsActual Revenue$1.24 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AReShape Lifesciences Announcement DetailsQuarterQ2 2025Date8/14/2025TimeAfter Market ClosesConference Call DateThursday, August 14, 2025Conference Call Time7:00AM ETUpcoming EarningsReShape Lifesciences' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) ReShape Lifesciences Earnings HeadlinesReshape Lifesciences Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comReShape Lifesciences Inc trading halted, news pendingAugust 15, 2025 | msn.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.September 13 at 2:00 AM | Brownstone Research (Ad)Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND TomorrowAugust 14, 2025 | finance.yahoo.com3 Penny Stocks to Watch Now, 8/14/25August 14, 2025 | msn.comVyome Therapeutics Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HINDAugust 14, 2025 | finanznachrichten.deSee More ReShape Lifesciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ReShape Lifesciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ReShape Lifesciences and other key companies, straight to your email. Email Address About ReShape LifesciencesReShape Lifesciences (NASDAQ:RSLS), headquartered in San Clemente, California, is a medical device company specializing in minimally invasive and non‐surgical therapies for obesity management and body contouring. The company’s core product portfolio includes endoscopic intragastric balloon systems that support physician‐led weight‐loss programs and non‐surgical cryolipolysis‐based devices for targeted adipose reduction without surgery. Under its ReShape Interventions division, the company markets a dual intragastric balloon system engineered to occupy gastric space, promote early satiety and aid comprehensive diet and lifestyle regimens. Through its OSPREY Medical division, ReShape provides non‐invasive body‐contouring platforms that harness controlled cooling and compression to reduce subcutaneous fat in outpatient aesthetic settings. Founded in 2010, ReShape Lifesciences has expanded beyond the United States to serve outpatient clinics and healthcare professionals in select European markets. The company partners with gastroenterologists, bariatric specialists and aesthetic practitioners to integrate its device technologies into multidisciplinary care pathways for patients seeking weight management and body‐shaping solutions. ReShape Lifesciences is guided by a leadership team with extensive expertise in medical device research, clinical development and regulatory compliance. The company continues to invest in product innovation and clinical studies aimed at enhancing the safety and efficacy of its minimally invasive and non‐invasive therapies in the growing obesity and aesthetic care markets.View ReShape Lifesciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Celsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
